Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A known ✓ | P27815 | 3/20 | 0.55 |
| ▸ | PDE4B known ✓ | Q07343 | 3/20 | 0.55 |
| ▸ | PDE4C known ✓ | Q08493 | 3/20 | 0.55 |
| ▸ | PDE4D known ✓ | Q08499 | 3/20 | 0.55 |
| ▸ | PDE5A known ✓ | O76074 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.54 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.54 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7020804 | 0.98 | ADORA2A (0.56) | ADORA2AADORA2BADORA1ADORA3PDE4A | |
| SCHEMBL10420652 | 0.89 | SIRT1 (0.66) | ADORA2BADORA1SIRT1SIRT3SIRT5 | |
| SCHEMBL7918903 | 0.82 | ADORA1 (0.57) | ADORA2AADORA2BADORA1ADORA3PDE4A | |
| SCHEMBL7022635 | 0.82 | SIRT1 (0.56) | ADORA2AADORA2BADORA1ADORA3SIRT1 | |
| SCHEMBL3178064 | 0.81 | SIRT1 (0.55) | ADORA2AADORA2BADORA1ADORA3PDE4A | |
| SCHEMBL7031457 | 0.81 | SIRT1 (0.55) | ADORA2AADORA2BADORA1ADORA3PDE4A | |
| SCHEMBL10859893 | 0.79 | SIRT1 (0.61) | ADORA2AADORA1PDE4APDE4BPDE4C | |
| SCHEMBL3119443 | 0.79 | SIRT1 (0.54) | ADORA2AADORA2BADORA1ADORA3PDE4A | |
| SCHEMBL10856971 | 0.79 | SIRT1 (0.61) | ADORA2AADORA1PDE4APDE4BPDE4C | |
| SCHEMBL13247926 | 0.78 | ADORA2B (0.53) | ADORA2AADORA2BADORA1ADORA3PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6531600-B1 | 8-substituted xanthines have a protective effect against the consequences of cerebral metabolic inhibition; cerebral vascular and neuronal degenerative disorders; 6-aminouracil intermediate is claimed | BEECHAM GROUP P.L.C. (GB) | 2003-03-11 | — | — | US | disclosed |
| EP-1120417-A2 | Xanthine derivatives for the treatment of cerebrovascular disorders | SMITHKLINE BEECHAM PHARMA GmbH (DE) | 2001-08-01 | — | — | EP | disclosed |
| US-6180791-B1 | REDUCING NITRO GROUPS TO FORM AMINO GROUPS | BEECHAM GROUP P.L.C. (GB) | 2001-01-30 | — | — | US | disclosed |
| US-5981535-A | FOR TREATMENT OF ALLERGIC DISORDERS ASSOCIATED WITH ATOPY, BRONCHODILATION TO TREAT DISORDERS OF THE RESPIRATORY TRACT IN A MAMMAL | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-11-09 | — | — | US | disclosed |
| US-5734051-A | TREATMENT OF CEREBROVASCULAR DISORDERS AND-OR DISORDERS ASSOCIATED WITH CEREBRAL SENILITY | BEECHAM GROUP (GB) | 1998-03-31 | — | — | US | disclosed |
| EP-0389282-A2 | Xanthinederivatives, process for their preparation and their pharmaceutical use | BEECHAM - WUELFING GmbH & Co. KG (DE) | 1990-09-26 | — | — | EP | disclosed |